First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Impact ledger

    SPDR S&P Biotech ETF (XBI): the developments shaping its investment case

    Follow the evidence affecting SPDR S&P Biotech ETF. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

    Research SPDR S&P Biotech ETF · $399/mo

    Test assumptions, examine opportunities, and save your research.

    Material developments

    2026-08-26
    Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 Firms
    Channel: Increased investor sentiment and capital flow into the biotechnology sector, particularly those focused on rare diseases and neurology.
    Bullish· 1-3m
    2026-09-08
    Eli Lilly Accelerates Biotech Acquisitions to Dilute GLP-1 Revenue Concentration
    Channel: Increased M&A activity in the biotech sector, potentially driving up valuations for target companies.
    Bullish· 1-3m
    2026-09-03
    NEJM Publishes Revolution Medicines Daraxonrasib NSCLC Data: 42% ORR, 16.0 Mo Survival
    Channel: Positive sentiment spillover for the biotechnology sector, particularly for companies with oncology pipelines or those developing targeted therapies.
    Bullish· 1-5d

    Event impact log

    36 events mapped to XBI since 2026-08-12. Evidence through 2026-09-29.

    DateEventChannelDirectionHorizonImpact
    2026-09-29Oncolytics Biotech Announces Publication of Pelareorep Data in Liver CancerGeneral positive sentiment for the biotechnology sector, particularly for oncology-focused small-cap companies with promising clinical data.Bullish1-3m0.10
    2026-09-29Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE TrialPositive news from a constituent company, especially regarding clinical trial progress, can contribute to overall sector sentiment, albeit with a very minor direct impact due to MBRX's small market cap.Bullish1-3m0.10
    2026-09-25ADARx Pharma Prices Upsized $446.3M IPO at $17 on NasdaqIndirect sentiment boost for the broader biotech sector; successful IPOs can attract more capital to the industry.Bullish1-5d0.40
    2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per ShareInclusion of ADRX into the ETF (if criteria met) and general sentiment for the biotech sector.Bullishintraday0.30
    2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17An upsized and successful biotech IPO can signal broader investor confidence in the sector, potentially leading to increased inflows into biotech ETFs.Bullish1-5d0.60
    2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/ShareImproved sector sentiment and investor confidence. A successful, upsized IPO in the biotech space can signal renewed institutional interest and risk appetite for the broader sector, potentially leading to increased inflows into biotech ETFs.Bullish1-3m0.60
    2026-09-24Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and OncologyIndirect impact through CLNN's weighting in the ETF and broader sector sentiment. Significant news from a component company can slightly influence the ETF, especially if it sets a trend for similar assets or technologies.watch1-3m0.20
    2026-09-23Longeveron Announces Exploration of All Options to Maximize Shareholder Value Following Phase 2b Trial ResultsBroader sentiment impact on small-cap biotech, particularly those with single-asset pipelines or recent clinical failures.Bearish1-5d0.20
    2026-09-21Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 StudyImproved sentiment for the biotechnology sector, particularly for companies with clinical-stage assets, due to a successful trial outcome from a constituent company.Bullish1-5d0.10
    2026-09-21Ionis slides over 40% year-to-date following late-stage clinical setbacksSector-wide sentiment. Increased valuation dispersion and clinical setbacks for a prominent ASO platform company can dampen investor enthusiasm for the broader biotech sector, especially those with high pipeline dependency.Bearish1-5d0.20
    2026-09-21Bristol Myers Squibb Posts $12.9B Revenue as Growth Portfolio Hits 60%Indirect sector sentiment and investor confidence in pharmaceutical innovation.Bullish1-3m0.40
    2026-09-21Ionis Pharmaceuticals faces pipeline pressure after pelacarsen and eplontersen trial setbacksSector sentiment. Significant setbacks for a prominent biotech company like Ionis can weigh on broader investor confidence in the sector, especially for companies with similar pipeline-driven risk profiles.Bearish1-3m0.40
    2026-09-21Ionis Pharmaceuticals trades down 40% following late-stage clinical setbacksNegative sentiment spillover to the broader biotechnology sector, particularly for companies with similar drug development risks or ASO platform technologies. IONS is a component of XBI.Bearish1-5d0.20
    2026-09-20Electra Therapeutics Sets Nasdaq IPO Terms to Raise Up to $347MGeneral sentiment towards the biotech sector and potential for new constituent.mixed1-3m0.40
    2026-09-20Electra Therapeutics Sets Terms for $347M Nasdaq IPOBroader sentiment indicator for the biotechnology sector, particularly for development-stage companies.watch1-3m0.20
    2026-09-20Electra Therapeutics sets terms for $347M Nasdaq IPO under ticker ETRADirect sentiment read-through for the broader biotech sector. IPO performance, especially for a significant raise, can influence investor perception of the sector's health and risk appetite.mixed1-5d0.40
    2026-09-19Electra Therapeutics IPO — $347MSector sentiment and capital allocation trends. A successful IPO could signal investor appetite for biotech, while a struggling one might indicate caution.watch1-3m0.10
    2026-09-18Electra Therapeutics, Inc. IPO — $350MSuccessful IPOs in a sector can attract generalist investor interest and capital flows into sector-specific ETFs.Bullish1-5d0.40
    2026-09-16COSCIENS Biopharma Inc. Convertible — $4.4MIndirect sentiment and capital availability for small-cap biotech sector. While COSCIENS is not a major component, its financing terms can be indicative of broader trends.watch1-3m0.20
    2026-09-15Citadel increases AbbVie position by over 500% amid defensive yield rotationWhile ABBV is biopharma, the 'defensive yield rotation' might favor larger, established players over the broader, often more volatile biotech sector represented by XBI.mixed1-3m0.30
    2026-09-15Citadel expands AbbVie stake over 500% in Q2 defensive positioning moveWhile large-cap pharma may see inflows, the broader biotech sector (represented by XBI) often includes more volatile, growth-oriented companies. Defensive positioning might lead to outflows from riskier biotech, but some larger, more established biotech components could benefit from sector sentimentmixed1-3m0.30
    2026-09-14FDA Approves Scholar Rock's Isembyld for Spinal Muscular AtrophyPositive sentiment spillover for the broader biotechnology sector, particularly for companies with novel drug candidates and rare disease focus.Bullish1-3m0.30
    2026-09-14FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMAIndirect positive sentiment for the biotechnology sector. A successful drug approval, especially for a novel mechanism, can boost investor confidence in the broader industry's innovation capacity.Bullish1-5d0.30
    2026-09-12FDA Approves Isembyld for Spinal Muscular AtrophyGeneral positive sentiment for the biotech sector, particularly for companies with successful clinical development and regulatory approvals.Bullish1-5d0.30
    2026-09-08Eli Lilly Accelerates Biotech Acquisitions to Dilute GLP-1 Revenue ConcentrationIncreased M&A activity in the biotech sector, potentially driving up valuations for target companies.Bullish1-3m0.60
    2026-09-03NEJM Publishes Revolution Medicines Daraxonrasib NSCLC Data: 42% ORR, 16.0 Mo SurvivalPositive sentiment spillover for the biotechnology sector, particularly for companies with oncology pipelines or those developing targeted therapies.Bullish1-5d0.60
    2026-09-02TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell TherapySector sentiment, capital allocation trends, small-cap biotech performance.watch1-3m0.10
    2026-08-28Biohaven Signs $795M Licensing Deal with SK Biopharm for OpakalimPositive sentiment spillover for the biotech sector, particularly for companies with promising early-stage assets or those engaged in licensing activities. BHVN is a component of XBI.Bullish1-5d0.30
    2026-08-27Mesoblast FY2026 Revenue Reaches $120.3M Led by RYONCIL Commercial LaunchImproved sentiment for the broader biotechnology sector, particularly for companies transitioning from R&D to commercialization, as MESO's success demonstrates viability.Bullish1-3m0.40
    2026-08-26FDA Approves Revolution Medicines' RASONQUE as First Targeted RAS InhibitorSector-wide positive sentiment from a significant drug approval, particularly for a novel mechanism of action in oncology. RVMD is a component of XBI.Bullish1-3m0.60
    2026-08-26Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 FirmsIncreased investor sentiment and capital flow into the biotechnology sector, particularly those focused on rare diseases and neurology.Bullish1-3m0.70
    2026-08-21Werewolf Therapeutics and Ambros Therapeutics announce merger agreement and concurrent $150 million private placementSector sentiment, increased M&A activity indicating potential for further consolidation.Bullish1-5d0.30
    2026-08-21Werewolf Therapeutics, Inc. to Acquire Ambros Therapeutics, Inc. ($548M)Indirect impact through sector sentiment. M&A activity can signal health or consolidation trends within the broader biotech industry.watch1-5d0.20
    2026-08-19Vogenx, Inc. IPO — $12MA successful IPO in the biotech sector, especially with strong over-allotment exercise, can signal positive investor sentiment for the broader industry, potentially leading to minor inflows or improved sentiment for biotech ETFs.Bullish1-5d0.10
    2026-08-17Valion Bio, Inc. Follow-On — $1.5MIndirect sentiment indicator for the biotech sector's funding environment. Continued private investment suggests a healthy ecosystem for innovation and potential future M&A targets.Bullish1-3m0.20
    2026-08-12Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage StudySentiment boost for the broader biotechnology sector. A significant positive clinical trial result, especially for a smaller company, can improve investor confidence in the sector's innovation and potential.Bullish1-5d0.40

    Continue this research

    Build your SPDR S&P Biotech ETF investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.

    This ledger is regenerated from Market Ontology's public event pipeline. View the XBI entity page →

    Research SPDR S&P Biotech ETF · $399/mo